Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response

Fig. 7

Combination of AMG9810 with bortezomib effectively targets MM tumor burden in vivo in the BM niche. a RPMI8226-CXCR4 (5 × 106) were intravenously (i.v.) injected into NSG mice and three days later were treated with subcutaneous bortezomib injections (0.5 mg/kg) twice a week, total of 6 injections, intraperitoneal AMG9810 injections (10 mg/kg) twice a week, total of 6 injections or the combination of both agents. On day 24 following MM cell inoculation, mice were killed and the human MM burden in the murine BM was evaluated. b, c Response of tumor burden, presented as percent of RPMI8226-CXCR4 MM cells in the BM, five mice per group. Data are presented as mean ± SE, **p < 0.01

Back to article page